Late-onset cytomegalovirus (CMV) in lung transplant recipients: Can CMV serostatus guide the duration of prophylaxis?

American Journal of Transplantation

Volumn 13, Issue 2, 2013, Pages 376-382

  Schoeppler, K E ^a   Lyu, D M ^b   Grazia, T J ^b   Crossno Jr , J T ^b   Vandervest, K M ^b   Zamora, M R ^b  

^a UNIVERSITY OF COLORADO HOSPITAL   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Acute rejection; cytomegalovirus (CMV); lung transplant; serostatus; valganciclovir

Indexed keywords

HYPERIMMUNE GLOBULIN; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ADULT; ARTICLE; CELLULAR IMMUNITY; CYTOMEGALOVIRUS INFECTION; DISEASE FREE SURVIVAL; FEMALE; GRAFT RECIPIENT; HUMAN; INFECTION PREVENTION; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION;

ADULT; AGED; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; RETROSPECTIVE STUDIES; TISSUE DONORS; TREATMENT OUTCOME;

EID: 84873097497     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04339.x     Document Type: Article

References (19)

1. Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779-795.
2. Palmer SM, Limaye AP, Banks M, et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: A randomized, controlled trial. Ann Intern Med 2010; 152: 761-769.
3. Costa C, Astegiano S, Terlizzi ME, et al. Evaluation and significance of cytomegalovirus-specific cellular immune response in lung transplant recipients. Transplant Proc 2011; 43: 1159-1161.
4. Lochmanova A, Lochman I, Tomaskova H,. Quantiferon-CMV test in prediction of cytomegalovirus infection after kidney transplantation. Transplant Proc 2010; 42: 3574-3577.
5. Lisboa LF, Kumar D, Wilson LE, Humar A,. Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia. Transplantation 2012; 9: 195-200.
6. Snyder LD, Medinas R, Chan C, et al. Polyfunctional cytomegalovirus- specific immunity in lung transplant recipients receiving valganciclovir prophylaxis. Am J Transplant 2011; 11: 553-560.
7. Giulieri S, Manuel O,. QuantiFERON®-CMV assay for the assessment of cytomegalovirus cell-mediated immunity. Expert Rev Mol Diagn 2011; 11: 17-25.
8. Manuel O, Husain S, Kumar D, et al. A prospective multi-center study of the Quantiferon-CMV® Assay for the prediction of cytomegalovirus disease in CMV D+/R- solid-organ transplant recipients [abstract]. Am J Transplant 2012; 12 (Suppl 3): 70-71.
9. Schnitzler MA, Woodward RS, Brennan DC, Spitznagel EL, Dunagan WC, Bailey TC,. The effects of cytomegalovirus serology on graft and recipient survival in cadaveric renal transplantation: Implications for organ allocation. Am J Kidney Dis 1997; 29: 428-434.
10. Schnitzler MA, Woodward RS, Brennan DC, Spitznagel EL, Dunagan WC, Bailey TC,. Impact of cytomegalovirus serology on graft survival in living related kidney transplantation: Implications for donor selection. Surgery 1997; 121: 563-568.
11. Danziger-Isakov LA, Delamorena M, Hayashi RJ, et al. Cytomegalovirus viremia associated with death or retransplantantion in pediatric lung-transplant recipients. Transplantation 2003; 75: 1538-1543.
12. Razonable RR, Rivero A, Rodriguez A, et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 2001; 184: 1461-1464.
13. Weinberg A, Hodges TN, Li S, Cai G, Zamora MR,. Comparison of PCR, antigenemia assay, and rapid blood culture for detection and prevention of cytomegalovirus disease after lung transplantation. J Clin Microbiol 2000; 38: 768-772.
14. Weinberg A, Schissel D, Giller R,. Molecular methods for cy- tomegalovirus surveillance in bone marrow transplant recipients. J Clin Microbiol 2002; 40: 4203-4206.
15. Zamora MR, Nicolls MR, Hodges TN, et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effect for preventions of CMV infection following lung transplantation. Am J Transplant 2004; 4: 1635-1642.
16. Stewart S, Fishbein MC, Snell GI, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant 2007; 26: 1229-1242.
17. Ugarte-Torres A, Hoegh-Petersen M, Liu Y, et al. Donor serostatus has an impact on cytomegalovirus-specific immunity, cytomegaloviral disease incidence, and survival in seropositive hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 2011; 17: 574-585.
18. Manuel O, Asberg A, Pange X, et al. Impact of genetic polymorphisms in cytomegalovirus glycoprotein B on outcomes in solid-organ transplant recipients with cytomegalovirus disease. Clin Infect Dis 2009; 49: 1160-1166.
19. Manuel O, Pang XL, Humar A, Kumar D, Doucette K, Preiksaitis JK,. An assessment of donor-to-recipient transmission patterns of human cytomegalovirus by analysis of viral genomic variants. J Infect Dis 2009; 199: 1621-1628.